Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma.

MLA

Margalit, Ofer, et al. “Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma.” The Oncologist, vol. 24, no. 8, Aug. 2019, pp. e671–76. EBSCOhost, https://doi.org/10.1634/theoncologist.2018-0333.

APA

Margalit, O., Mamtani, R., Kopetz, S., Yang, Y.-X., Lawrence, Y. R., Abu-Gazala, S., Reiss, K. A., Golan, T., Halpern, N., Aderka, D., Giantonio, B., Shacham-Shmueli, E., & Boursi, B. (2019). Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma. The Oncologist, 24(8), e671–e676. https://doi.org/10.1634/theoncologist.2018-0333

Chicago

Margalit, Ofer, Ronac Mamtani, Scott Kopetz, Yu-Xiao Yang, Yaacov R Lawrence, Samir Abu-Gazala, Kim A Reiss, et al. 2019. “Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma.” The Oncologist 24 (8): e671–76. doi:10.1634/theoncologist.2018-0333.